Tue. 16 Apr 2024, 5:22am ET
Benzinga
Biotech, Large Cap, News, Health Care, General
At more than three years (median follow-up of 41.3 months), results showed Imfinzi plus chemotherapy reduced the risk of death by 26% versus chemotherapy alone. The median OS was 12.9 months for Imfinzi plus chemotherapy versus 11.3 months for chemotherapy alone.
More than twice as many patients on the Imfinzi-based regimen were alive at three years versus chemotherapy alone (14.6% versus 6.9%).